NCT04172194CompletedNot Applicable
Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepatocellular Carcinomas
Centre Hospitalier Universitaire de Nice1 site in 1 country64 target enrollmentStarted: January 1, 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 64
- Locations
- 1
- Primary Endpoint
- overall survival
Study Overview
Brief Summary
Background: The association of transcatheter arterial chemotherapy infusion (TAC) with percutaneous ablation (PT) has been introduced as a method to increase the ablative zone. The aim of this study was to evaluate the efficacy of PT and TAC performed in a single session for HCCs between 30 and 50 mm or oligonodular up to 30 mm.
Methods: Thirty patients with a histologically proven HCC, uninodular between 30 and 50 mm or oligonodular (n≤3) up to 30 mm, treatment-naïve and non-metastatic, received combination treatment ("PT+TAC group"). A "control" group consisted of 34 patients with uninodular HCC up to 30 mm without any poor prognostic criteria treated with PT alone ("PT group").
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 19 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •hepatocellular carcinoma pouved by pathology,
Exclusion Criteria
- •metastases
Outcomes
Primary Outcomes
overall survival
Time Frame: 30 minutes
death
Secondary Outcomes
- relapse free survival(30 minutes)
- tolerance(30 minutes)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaEsophagogastric VaricesNCT05017922Qilu Hospital of Shandong University89
Withdrawn
Phase 3
Combination Treatment for Advanced Liver CancerHepatocellular CarcinomaHepatic Portal Vein Tumor InvasionNCT02149771Shanghai Zhongshan Hospital
Recruiting
Not Applicable
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTTHepatocellular Carcinoma Non-resectableNCT04967495Second Affiliated Hospital of Guangzhou Medical University171
Completed
Phase 2
Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or CarboplatinUnresectable Intrahepatic CholangiocarcinomaNCT01648023Robert C. Martin49
Completed
Phase 1
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCCHepatocellular Carcinoma Non-resectableNCT04592029Second Affiliated Hospital of Guangzhou Medical University36